Gossamer Bio Inc. (NASDAQ: GOSS) has finalized a milestone-based private placement financing valued at up to $250 million in gross proceeds, anchored by $150 million in committed capital.
The initial $25 million is scheduled to close on Sunday, with an additional $125 million contingent on the U.S. Food and Drug Administration accepting the company’s new drug application for seralutinib in pulmonary arterial hypertension by 2026. The NDA submission is planned for September 2026, and if accepted, the full $150 million would be received this year.
Net proceeds, combined with existing cash, are expected to fund operations through 2028. The financing includes warrants exercisable upon FDA approval of seralutinib, which could generate up to $100 million in additional gross proceeds if exercised at $0.187 per share. These warrants expire 30 days after FDA approval notice or five years from issuance, whichever comes first.
At the initial closing, Gossamer Bio will issue pre-funded warrants for $25 million at $0.1399 per warrant. The second closing’s warrant price will equal the lesser of $0.1399 or the five-day volume-weighted average price of the company’s common stock prior to closing, minus the exercise price.
The financing round includes participation from EcoR1 Capital, 683 Capital Partners LP, RA Capital Management, Coastlands Capital, Samsara BioCapital, and Rock Springs Capital. Leerink Partners and Cantor are serving as joint placement agents.
